ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

IG Report Clears Shubik Of Conflict Of Interest Change

October 6, 1978

Drug Development Budget Cuts Force Early End To P388 Screening Contracts

January 9, 1987

Dingell Asks FDA To Explain Failure To Curtail ESA Ads.

June 15, 2007

ACS Creates $1 Billion Nationwide Organization, Taking Fiduciary Control From 12 Divisions

November 18, 2011

Nucynta ER Approved For Managing Chronic Pain In Adults

September 30, 2011

In Brief: Ingell Vows To Broaden Indirect Cost Inquiry; Gallo, Fauci Make ‘Most Prolific Scientist’ List

February 7, 1992